Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018
- Author:
Jeong Mi KIM
1
;
Sang Soo KIM
Author Information
- Publication Type:Review
- Keywords: Atherosclerosis; Cardiovascular disease; Diabetes mellitus; type 2; Hyperglycemia; Patient-centered care
- MeSH: Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Comorbidity; Consensus; Diabetes Mellitus; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hyperglycemia; Insulin; Patient Preference; Patient-Centered Care; Renal Insufficiency, Chronic
- From:Journal of Korean Diabetes 2019;20(1):6-9
- CountryRepublic of Korea
- Language:Korean
- Abstract: In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”
